ArticleAnnals of surgical oncology2026
Radical Antegrade Modular Pancreatosplenectomy Versus Standard Resection in T3 Body and Tail Pancreatic Ductal Adenocarcinoma: A Multicenter Retrospective Cohort Study.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe optimal operation for T3 body and tail pancreatic ductal adenocarcinoma (PDAC) remains uncertain. Radical antegrade modular pancreatosplenectomy (RAMPS) was designed to facilitate systematic posterior dissection and lymphadenectomy, but whether its survival benefit varies by anatomic or molecular risk is unclear.
methodsThis multicenter retrospective cohort study included patients with pathologically confirmed T3 body and tail PDAC who underwent upfront RAMPS or standard retrograde pancreatosplenectomy (SRPS) at three high-volume centers from January 2014 to December 2024. Stabilized weighting was used to balance baseline covariates. The primary outcome was recurrence-free survival (RFS); secondary outcomes included overall survival (OS) and perioperative outcomes. Subgroup effects according to splenic vessel involvement and KRAS/TP53 alterations were assessed using adjusted interaction models.
resultsAmong 695 patients, 352 underwent RAMPS and 343 underwent SRPS. After stabilized weighting, baseline characteristics were well balanced. RAMPS was associated with longer RFS than SRPS (adjusted hazard ratio [HR] 0.46; 95% confidence interval [CI] 0.38-0.55; P < 0.001) and improved OS. The RFS benefit was pronounced in patients with splenic artery involvement (HR 0.24), splenic vein involvement (HR 0.35), TP53 mutations (HR 0.43), and KRAS mutations (HR 0.43). Formal interaction evidence remained robust for splenic vessel involvement after false discovery rate (FDR) correction. The molecular interaction evidence was attenuated after FDR correction and multiple imputation and should be considered exploratory.
conclusionsRAMPS was associated with improved RFS and OS in T3 body and tail PDAC, especially in tumors with splenic vessel involvement. These findings support a risk-adapted surgical strategy and require prospective validation.
Indexed as
Identifiers
42832147What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.